A randomized, double-blind comparative clinical study evaluating the impact of an investigational product in managing post-operative inflammation in orthopedic surgeries. - NI

Advanced Vital Enzymes P. Ltd. (Advenza)0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年8月19日

试验速览

暂无简介。

•1.Patients with 25-50 years of age (both inclusive);2.Patients electively posted for orthopedic surgery;3.Patient without any suspected or confirmed infection and receiving treatment for same;4.Willing to give informed consent for the study.

•1.Patients undergoing emergency surgery;
•2.Patients receiving immunosuppressive agents;
•3.Allergy, sensitivity, or contraindication to any interventional product;
•4.Patient with hepatic and or renal disorder, bleeding disorders, menorrhagia, hematuria and hematemesis;
•5.History of gastric ulcer or bleeding diathesis;
•6.Currently receiving cytotoxic therapy, or have received it within the last three months;
•7.Patients treated with any investigational drug in the preceding 4 weeks;
•8.Female patients with a positive pregnancy test or lactating;
•9.Patients with uncontrolled diabetes mellitus or any other metabolic disorder;
•10.Seriously ill and moribund patients with complications;
•11.Patients unable to comply with the treatment regimen;
•12.History of use of recreational drugs within 12 months before receiving the study drugs;
•13.Patients with any other condition that, in the opinion of the investigator, does not justify the inclusion of the patient in the study.

发起方

Advanced Vital Enzymes P. Ltd. (Advenza)